{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:49:29Z","timestamp":1762955369283},"reference-count":124,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprclinrheum.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.berh.2014.10.001","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T19:25:49Z","timestamp":1414783549000},"page":"747-763","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Adverse effects of TNF inhibitors in SpA: Are they different from RA?"],"prefix":"10.1016","volume":"28","author":[{"given":"Percival D.","family":"Sampaio-Barros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene E.","family":"van der Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2014.10.001_bib1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification\u00a0criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of the diagnostic criteria for ankylosing spondylitis; a proposal for the modification of the New York criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib4","first-page":"S67","article-title":"Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs","volume":"20","author":"van der Horst-Bruinsma","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib7","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiografically defined sacroiliitis","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib9","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.140056","article-title":"Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial","volume":"41","author":"Song","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"Van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2014.10.001_bib12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib14","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years\u2013early clinical response predicts long-term outcome","volume":"50","author":"Baraliakos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2014.10.001_bib15","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar4244","article-title":"Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years","volume":"15","author":"Baraliakos","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib16","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","article-title":"Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204195","article-title":"Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis","author":"Kay","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib18","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3899\/jrheum.131270","article-title":"Ten-year followup of infliximab therapy in rheumatoid\u00a0arthritis patients with severe, longstanding refractory disease: a cohort study","volume":"41","author":"De Keyser","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/ket333","article-title":"Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data","volume":"53","author":"Morgan","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2014.10.001_bib20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.720","article-title":"Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension","author":"Keystone","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib23","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER","volume":"8","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib24","first-page":"2433","article-title":"Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients","volume":"33","author":"Duclos","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib26","first-page":"964","article-title":"Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA","volume":"27","author":"Pavelka","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","article-title":"Ten years with biologics: to whom do data on effectiveness and safety apply?","volume":"50","author":"Simard","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2014.10.001_bib28","first-page":"857","article-title":"Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scir\u00e9","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib29","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib30","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib31","first-page":"510","article-title":"Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis","volume":"34","author":"Baraliakos","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib32","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/annrheumdis-2013-203327","article-title":"Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib33","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2014.10.001_bib35","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","article-title":"Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety","volume":"38","author":"Komano","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","article-title":"Time-dependent increased risk for serious infection from continuous use of Tumor Necrosis Factor antagonists over three years in patients with rheumatoid arthritis","volume":"64","author":"Sakai","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2014.10.001_bib37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"Van Dartel","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/pds.3238","article-title":"Comparative safety of infliximab and etanercept on the risk of serious infections \u2013 does the association vary by patient characteristics?","volume":"21","author":"Toh","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.berh.2014.10.001_bib39","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"issue":"Suppl.","key":"10.1016\/j.berh.2014.10.001_bib40","first-page":"47","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib41","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib43","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti\u2013tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/1756-185X.12188","article-title":"Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia","volume":"17","author":"Navarra","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib45","first-page":"145","article-title":"Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results","volume":"51","author":"Titton","year":"2011","journal-title":"Braz J Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib46","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib47","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00296-014-2945-y","article-title":"Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0","volume":"34","author":"Cobo-Iba\u00f1ez","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2014.10.001_bib48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib49","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-TNF therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2014.10.001_bib50","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti\u2013TNF-agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2014.10.001_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib52","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar3497","article-title":"The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study","volume":"13","author":"Zhang","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib53","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garcia-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1756-185X.12154","article-title":"Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs","volume":"16","author":"Lee","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib55","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar2868","article-title":"Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients","volume":"11","author":"Charpin","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib56","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib57","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2014.10.001_bib58","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1136\/annrheumdis-2014-205246","article-title":"Vaccines and biologics","volume":"73","author":"Ferreira","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib59","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/ar4127","article-title":"Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs","volume":"15","author":"Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib60","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","article-title":"TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients","volume":"51","author":"Fran\u00e7a","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2014.10.001_bib61","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib62","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapies: does the risk change with the time since start of treatment?","volume":"11","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib63","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides \u2013 a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib65","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","author":"Mercer","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib67","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/art.38339","article-title":"Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden","volume":"66","author":"Hellgren","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/03009742.2013.834961","article-title":"Risk of serious infection, opportunistic infections, inflammatory bowel diseases, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis","volume":"43","author":"van der Heijde","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib69","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"for the Club Rhumatismes et Inflammation Section of the SFR. Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2014.10.001_bib70","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4582","article-title":"Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study","volume":"16","author":"Kaltsonoudis","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib71","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","article-title":"Initiation of anti-TNF therapy and the risk of optic neuritis: from the Safety Assessment of Biologic ThERapy (SABER) Study","volume":"155","author":"Winthrop","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.berh.2014.10.001_bib72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrrheum.2011.168","article-title":"Cardiovascular safety of biologic therapies for the treatment of RA","volume":"8","author":"Greenberg","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/art.30654","article-title":"Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis","volume":"64","author":"Ljung","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.1554","article-title":"Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis","author":"van Sijl","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib75","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrrheum.2013.197","article-title":"The safety of biologic therapies in RA-associated interstitial lung disease","volume":"10","author":"Janl","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib76","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pds.3409","article-title":"Association between anti-TNF-\u03b1 therapy and interstitial lung disease","volume":"22","author":"Herrington","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.berh.2014.10.001_bib77","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","article-title":"Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort","volume":"13","author":"Piga","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2014.10.001_bib78","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/pds.3354","article-title":"Association between anti-TNF-\u03b1 therapy and all-cause mortality","volume":"21","author":"Herrington","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.berh.2014.10.001_bib79","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.30247","article-title":"Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents","volume":"63","author":"Raaschou","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib80","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ejim.2011.06.006","article-title":"Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications","volume":"22","author":"El Maghraoui","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.berh.2014.10.001_bib81","first-page":"2226","article-title":"Prevalence of the spondyloarthritides in patients with uveitis","volume":"31","author":"Linder","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib82","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2003.07.011","article-title":"Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases","volume":"111","author":"Monnet","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.berh.2014.10.001_bib83","first-page":"2198","article-title":"Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis","volume":"27","author":"Pato","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib84","first-page":"484","article-title":"An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA group","volume":"31","author":"Sampaio-Barros","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib85","first-page":"2568","article-title":"The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27","volume":"32","author":"Linssen","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.berh.2014.10.001_bib86","first-page":"1277","article-title":"Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period","volume":"30","author":"Munoz-Fernandez","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib87","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/S0161-6420(02)01292-7","article-title":"Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis","volume":"109","author":"El-Shabrawi","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.berh.2014.10.001_bib88","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.berh.2014.10.001_bib90","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/IAE.0b013e3181eac7a6","article-title":"Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.berh.2014.10.001_bib91","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.berh.2014.10.001_bib92","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.20754","article-title":"Effect of etanercept on iritis in patients with ankylosing spondylitis","volume":"50","author":"Rosenbaum","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib93","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib94","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib95","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib96","first-page":"630","article-title":"Decreased recurrence rate of uveitis in ankylosing spondylitis treated with adalimumab: an interim analysis","volume":"28","author":"van der Horst-Bruinsma","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib97","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/717598","article-title":"Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience","volume":"2014","author":"Cordero-Coma","year":"2014","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.berh.2014.10.001_bib98","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","article-title":"Long-term treatment with golimumab for severe uveitis","volume":"22","author":"Miserocchi","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.berh.2014.10.001_bib99","first-page":"238","article-title":"Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis","volume":"28","author":"Mart\u00edn-Mola","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000358324","article-title":"Certolizumab-induced uveitis: a case report and review of the literature","volume":"5","author":"Moisseiev","year":"2014","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.berh.2014.10.001_bib101","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.001_bib102","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib103","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study","volume":"48","author":"Fouache","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2014.10.001_bib104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2014.10.001_bib106","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib107","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.001_bib108","first-page":"40","article-title":"A\u00a0case of palmoplantar pustulosis induced by certolizumab pegol: new anti-TNF-alpha demonstrates the same class effect","volume":"5","author":"Shelling","year":"2012","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"10.1016\/j.berh.2014.10.001_bib109","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","article-title":"The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series","volume":"8","author":"Afzali","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.berh.2014.10.001_bib110","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.berh.2014.10.001_bib111","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Groupe d'Etude Th\u00e9rapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy","volume":"8","author":"Rahier","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.berh.2014.10.001_bib112","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000358288","article-title":"Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies","volume":"89","author":"Barthel","year":"2014","journal-title":"Digestion"},{"key":"10.1016\/j.berh.2014.10.001_bib113","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jbspin.2007.06.011","article-title":"Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2014.10.001_bib114","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/rheumatology\/27.2.163-b","article-title":"Ileocolonoscopy and spondarthritis","volume":"27","author":"Mielants","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib115","first-page":"1542","article-title":"Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic, and genetic features in relation to the type of histology. A prospective study","volume":"18","author":"Mielants","year":"1991","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib116","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.3899\/jrheum.100269","article-title":"pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease","volume":"37","author":"de Vries","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib117","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.berh.2014.10.001_bib118","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2014.10.001_bib119","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2014.10.001_bib120","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.berh.2014.10.001_bib121","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.berh.2014.10.001_bib122","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A\u00a0randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.berh.2014.10.001_bib123","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.001_bib124","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694214000837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694214000837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T15:49:54Z","timestamp":1717516194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694214000837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1521694214000837"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2014.10.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse effects of TNF inhibitors in SpA: Are they different from RA?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2014.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}